De los 3 grupos de tratamiento que existen para el cáncer de mama triple negativo metastásico, el de la inmunoterapia , tiene 2 fármacos aprobados en Europa y solo tenemos acceso en España a uno de ellos. Otro de los grupos, el de los inhibidores PARP que se usa para el cáncer de mama de hereditario no hay acceso en por qué no se ha aprobado el reembolso y el grupo de los anticuerpos conjugados tampoco no hay acceso a ellos.
Si quieres ampliar la noticia pincha en el enlace:
| Cookie | Duración | Descripción |
|---|---|---|
| cookielawinfo-checkbox-analytics | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics". |
| cookielawinfo-checkbox-functional | 11 months | The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional". |
| cookielawinfo-checkbox-necessary | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary". |
| cookielawinfo-checkbox-others | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other. |
| cookielawinfo-checkbox-performance | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance". |
| viewed_cookie_policy | 11 months | The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data. |